Granulocyte colony–stimulating factor–mobilized peripheral blood stem cells in β-thalassemia patients

Li, Karen; Wong, Ambrose H.; Li, Chi Kong; Shing, Matthew Ming Kong; Chik, Ki Wai; Tsang, Kam Sze; Lai, Hsin‐Cheng; Leung, Ting Fan; Yuen, Patrick Man Pan

doi:10.1016/s0301-472x(98)00045-9

Cited by 21 publications

(17 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We have previously shown that the yield of CD34 ϩ cells from thalassaemia patients does not differ from normal healthy donors. 19 Furthermore, in the current study the yield of CD34 ϩ cells from the healthy donors did not differ from the non-cancer patients. The results suggest that the mobilization kinetics of the two groups are similar.…”

Section: Discussionmentioning

confidence: 41%

Single vs twice daily G-CSF dose for peripheral blood stem cells harvest in normal donors and children with non-malignant diseases

Lee

Shing

et al. 2000

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:The optimal dose and schedule of G-CSF for mobilization of peripheral blood stem cells (PBSC) is not well defined. G-CSF mobilization was performed in a group of healthy donors and paediatric patients for autologous back-up before receiving allogeneic stem cell transplant. Seventeen consecutive subjects who received G-CSF at 5 g/kg/dose twice daily (group A) were compared with a historical control group of 25 subjects who received a single daily dose of 10 g/kg/day G-CSF (group B). Double blood volume apheresis for PBSC collection was started on day 5. G-CSF was continued and apheresis repeated until the targeted CD34 ϩ cell dose was achieved. Both groups were comparable for sex, age, body weight and reason for PBSC collection. Over two-thirds of the subjects in both groups were less than 16 years of age. The G-CSF priming and apheresis were well tolerated. When the first day apheresis products were analyzed, group A resulted in significantly higher yield of total nucleated cells (5.91 vs 3.92 ؋ 10 8 /kg, P ‫؍‬ 0.013), mononuclear cells (5.73 vs 3.92 ؋ 10 8 /kg, P ‫؍‬ 0.017), CD34 ؉ cells (2.80 vs 1.69 ؋ 10 6 /kg, P ‫؍‬ 0.049) and colony-forming units (107 vs 54 ؋ 10 4 /kg, P ‫؍‬ 0.010) as compared with group B. We conclude that the two dose schedule is more efficient in mobilizing PBSC in normal donors and children with non-malignant diseases. This approach may reduce the number of aphereses required and thus reduce the transplant cost. Bone Marrow Transplantation (2000) 25, 931-935.

show abstract

Section: Discussionmentioning

confidence: 41%

Single vs twice daily G-CSF dose for peripheral blood stem cells harvest in normal donors and children with non-malignant diseases

Lee

Shing

et al. 2000

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…13,16,17 Furthermore, adult subjects will be treated on these trials, in contrast to the primarily pediatric subjects treated for metabolic disorders and severe immune deficiencies. 18 Li et al 19 previously administered G-CSF in 20 patients with b thalassemia aged 3-to 21-year-old, but no quantitative data on the yield or composition of the apheresis products were provided. Yannaki et al 20 mobilized 23 thalassemic adults with G-CSF with or without pretreatment with hydroxyurea.…”

Section: Resultsmentioning

confidence: 99%

Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation

Boulad¹,

Wang

et al. 2014

Blood

View full text Add to dashboard Cite

show abstract

“…Copy numbers are typically kept low to decrease the risk of insertional oncogenesis, and the clinical result of a higher copy number is unknown. 88 Li et al in 1999 showed that β-thalassemia patients could undergo granulocyte colony-stimulating factor (G-CSF) mobilization. 89 In 2012, Yannaki and colleagues studied different mobilization methods in 23 patients with β-thalassemia.…”

Section: Clinical Trials For the Hemoglobinopathiesmentioning

confidence: 99%

“…88 Li et al in 1999 showed that β-thalassemia patients could undergo granulocyte colony-stimulating factor (G-CSF) mobilization. 89 In 2012, Yannaki and colleagues studied different mobilization methods in 23 patients with β-thalassemia. 90 Studying patients with and without splenectomy, they found that nonsplenectomized patients tolerated G-CSF, but splenectomized patients showed hyperleukocytosis and could not tolerate it.…”

Section: Clinical Trials For the Hemoglobinopathiesmentioning

confidence: 99%

Gene Therapy for Hemoglobinopathies

Dong

Breda

Rivella

2015

Translating Gene Therapy to the Clinic

View full text Add to dashboard Cite

Granulocyte colony–stimulating factor–mobilized peripheral blood stem cells in β-thalassemia patients

Cited by 21 publications

References 27 publications

Single vs twice daily G-CSF dose for peripheral blood stem cells harvest in normal donors and children with non-malignant diseases

Single vs twice daily G-CSF dose for peripheral blood stem cells harvest in normal donors and children with non-malignant diseases

Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation

Gene Therapy for Hemoglobinopathies

Contact Info

Product

Resources

About